LeaderPortfolio
Legorreta
P
Rank #898
UNITED STATEShealthcareInvestments

Pablo Legorreta

Net Worth
$4.697B
-1.73% (24h)
Pablo Legorreta is a Mexican-American billionaire and a prominent figure in the finance and investment industry. As the founder, CEO, and Chairman of Royalty Pharma plc, he has pioneered the acquisition of pharmaceutical royalty streams, transforming how drug development is financed. His estimated net worth is $4.2 billion, a testament to his success in the Investments sector. Legorreta's career began in investment banking before he established Royalty Pharma in 1996, which has since deployed billions to support biopharmaceutical innovation. He is also involved in various philanthropic initiatives and serves on multiple boards, reflecting his commitment to advancing scientific research and healthcare.

How to read Pablo Legorreta's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Pablo Legorreta, we anchor the narrative to Royalty Pharma and Investments, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $4.697B alongside global rank #898, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (UNITED STATES) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life and Education

Pablo Legorreta was born in Mexico and later became a U.S. citizen. He earned a Bachelor of Science degree in industrial engineering from Universidad Iberoamericana in Mexico City.

Rise to Success

Legorreta began his career at Lazard Frères, where he gained experience in mergers and acquisitions. In 1996, he founded Royalty Pharma, which revolutionized the financing of drug development by acquiring pharmaceutical royalty streams. Under his leadership, Royalty Pharma has become the world's largest acquirer of pharmaceutical royalty streams, deploying over $25 billion to support research across academic institutions, nonprofits, biotech firms, and global pharmaceutical companies. The company went public in 2020.

Key Business Strategies

Legorreta's primary business venture is Royalty Pharma, a company specializing in acquiring pharmaceutical royalty streams. This innovative approach has allowed Royalty Pharma to collect revenue from blockbuster drugs like Humira, Imbruvica, and Lyrica. His strategy includes acquiring royalties from drugs in development and funding research and development. He also co-founded Pharmakon Advisors, a leading provider of debt capital to the life sciences industry.

Philanthropy

Legorreta and his wife, Almudena, are involved in philanthropy. They have made significant donations to medical research institutions, including a $25 million gift to Brown University's Legorreta Cancer Center. They also contributed $5 million to Brigham and Women's Hospital for kidney transplantation research. Additionally, Legorreta founded and chairs Alianza Médica para la Salud, a non-profit organization focused on enhancing healthcare education in Latin America.

Career Timeline

2020

Royalty Pharma IPO

Took Royalty Pharma public on the Nasdaq.

1996

Founded Royalty Pharma

Established Royalty Pharma, pioneering the acquisition of pharmaceutical royalty streams.

1990

M&A Banker

Transferred to Lazard Frères in New York, continuing in mergers and acquisitions.

1987

M&A Banker

Began career at Lazard Frères in Paris, focused on mergers and acquisitions.

Philanthropic Impact

Cancer Research$25M

Legorreta Cancer Center

Donation to Brown University to advance cancer research.

Medical Research$5M

Kidney Transplantation Research

Contribution to Brigham and Women's Hospital for kidney transplantation research.

Healthcare EducationN/A

Alianza Médica para la Salud

Enhancing healthcare education in Latin America

Key Business Ventures & Holdings

CompanyStakeValue
Royalty Pharma PLC$0.17M

Net Worth History

In-Depth Analysis

Early Life and Education

Pablo Legorreta was born in Mexico and later became a U.S. citizen. He earned a Bachelor of Science degree in industrial engineering from Universidad Iberoamericana in Mexico City.

Rise to Success

Legorreta began his career at Lazard Frères, where he gained experience in mergers and acquisitions. In 1996, he founded Royalty Pharma, which revolutionized the financing of drug development by acquiring pharmaceutical royalty streams. Under his leadership, Royalty Pharma has become the world's largest acquirer of pharmaceutical royalty streams, deploying over $25 billion to support research across academic institutions, nonprofits, biotech firms, and global pharmaceutical companies. The company went public in 2020.

Key Business Strategies

Legorreta's primary business venture is Royalty Pharma, a company specializing in acquiring pharmaceutical royalty streams. This innovative approach has allowed Royalty Pharma to collect revenue from blockbuster drugs like Humira, Imbruvica, and Lyrica. His strategy includes acquiring royalties from drugs in development and funding research and development. He also co-founded Pharmakon Advisors, a leading provider of debt capital to the life sciences industry.

Philanthropy

Legorreta and his wife, Almudena, are involved in philanthropy. They have made significant donations to medical research institutions, including a $25 million gift to Brown University's Legorreta Cancer Center. They also contributed $5 million to Brigham and Women's Hospital for kidney transplantation research. Additionally, Legorreta founded and chairs Alianza Médica para la Salud, a non-profit organization focused on enhancing healthcare education in Latin America.

Data Sources & Methodology

Figures for Pablo Legorreta are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.